Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Learn More
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Learn More
Hemophilia B
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Immune Deficiencies Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Learn More
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Antibody-mediated kidney transplant rejection Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
How to Enroll into a Study

Find out if enrolling in a clinical trial is right for you.

Learn More
Product Pipeline

Delve into our portfolio of new products, improved products and manufacturing expertise.

Learn More
Our Products

Discover CSL's life-saving therapies.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list